Variable | Univariate analysis | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|---|
acquisition hazard ratio, (95% CI) | P value | clearance hazard ratio, (95% CI) | P value | acquisition hazard ratio, (95% CI) | P value | clearance hazard ratio, (95% CI) | P value | |
Baseline transition rate (/day) | Â | Â | Â | Â | 0.005 | Â | 0.01 | Â |
 Age | 0.90 (0.74–1.09) | 0.271 | 1.10 (0.91–1.33) | 0.318 |  |  |  |  |
 Sex | 0.41 (0.08–1.98) | 0.268 | 2.38 (0.49–11.46) | 0.281 |  |  |  |  |
Cumulative antibiotic exposure (days of therapy) | ||||||||
 Carbapenem | 1.09 (1.02-1.16) b | 0.007 | 1.0 (0.94–1.06) | 0.908 | 1.08 (1.01-1.16) b | 0.020 | 1.07 (0.99–1.17) | 0.083 |
 Glycopeptide | 1.04 (0.98–1.11) | 0.209 | 1.1 (1.0–1.2) | 0.140 | - |  | - |  |
 Non-carbapenem Beta-lactam | 0.9 (0.78–1.100) | 0.340 | 1.19 (1.05-1.34) b | 0.024 | 0.97 (0.81–1.15) | 0.711 | 1.25 (1.07-1.46) b | 0.004 |
 Antifungus | 1.02 (0.94–1.1) | 0.594 | 1.1 (0.97–1.1) | 0.196 | - |  | - |  |
 Miscellaneous | a |  | a |  | - |  | - |  |